<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Misra-Press, Anita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Rossi, Maddalena</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">SBRT as Effective Treatment Option for Medically Operable Stage I NSCLC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-19 09:31:56</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">This retrospective nonrandomized analysis demonstrated no significant difference in overall survival between patients with stage I non–small cell lung cancer who were treated with the traditional surgical approach compared with medically operable patients who refused surgery, were older, and opted for stereotactic body radiation therapy because of its high control rates and low toxicity.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>